STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs

With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Aditya Prakash, Mavuduru, Ravimohan S., Bora, Girdhar Singh, Devana, Sudheer K, Singh, Shrawan K., Mandal, Arup K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034411/
https://www.ncbi.nlm.nih.gov/pubmed/30034127
http://dx.doi.org/10.4103/iju.IJU_378_17
Descripción
Sumario:With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well-conducted randomized controlled trials and were shown to improve outcomes. However, this paradigm shift in the treatment has also raised some queries. This mini review reflects upon the four landmark trials and tries to provide some perspective about the decision-making process for the patients with hsMPC.

Ejemplares similares